Entasis Therapeutics to Present at the 28th Annual Credit Suisse Healthcare Conference
|Details of the presentation are below:
|Event:||28th Annual Credit Suisse Healthcare Conference|
|Date:||Tuesday, November 12, 2019|
|Time:||4:45 – 5:15 PM MST|
Additionally, Dr. Gutch will hold 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with Company management should contact their
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
Entasis Company Contact
Investor Relations Contact
Source: Entasis Therapeutics Holdings Inc.